Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Cytomx Thera (CTMX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 510,202
  • Shares Outstanding, K 45,311
  • Annual Sales, $ 59,500 K
  • Annual Income, $ -84,600 K
  • 60-Month Beta 0.57
  • Price/Sales 8.32
  • Price/Cash Flow N/A
  • Price/Book 3.96

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.54
  • Number of Estimates 7
  • High Estimate -0.34
  • Low Estimate -0.74
  • Prior Year -0.35
  • Growth Rate Est. (year over year) -54.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.94 +25.95%
on 04/25/19
11.49 -2.00%
on 05/13/19
+1.27 (+12.71%)
since 04/18/19
3-Month
8.94 +25.95%
on 04/25/19
19.20 -41.35%
on 02/25/19
-6.33 (-35.99%)
since 02/21/19
52-Week
8.94 +25.95%
on 04/25/19
27.20 -58.60%
on 07/25/18
-13.31 (-54.17%)
since 05/21/18

Most Recent Stories

More News
CytomX Therapeutics Announces Presentations at 2019 ASCO Annual Meeting

CytomX Therapeutics, Inc. (Nasdaq:CTMX) a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody(TM) therapeutic...

CTMX : 11.26 (+3.02%)
Relatively Good Performance Detected in Shares of Cytokinetics Inc in the Biotechnology Industry (CYTK , CTMX , FLXN , CHRS , SGMO )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

CYTK : 10.79 (+3.06%)
CTMX : 11.26 (+3.02%)
FLXN : 13.13 (+5.04%)
CytomX Therapeutics (CTMX) Reports Q1 Loss, Tops Revenue Estimates

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 41.51% and 116.96%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

CTMX : 11.26 (+3.02%)
CytomX Therapeutics Announces First Quarter 2019 Financial Results

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody(TM) therapeutic...

CTMX : 11.26 (+3.02%)
Cytomx Therapeut Down 22.8% Since SmarTrend Downtrend Call (CTMX)

SmarTrend identified a Downtrend for Cytomx Therapeut (NASDAQ:CTMX) on February 27th, 2019 at $12.97. In approximately 2 months, Cytomx Therapeut has returned 22.79% as of today's recent price of $10.01....

CTMX : 11.26 (+3.02%)
CytomX Therapeutics to Present at the Bank of America Merrill Lynch 2019 Health Care Conference

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody(TM) therapeutic...

CTMX : 11.26 (+3.02%)
Best Relative Performance in the Biotechnology Industry Detected in Shares of Acadia Pharmaceu (ACAD , CTMX , EXAS , CLVS , EXEL )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

CTMX : 11.26 (+3.02%)
EXAS : 96.95 (+0.95%)
ACAD : 25.54 (+5.41%)
CytomX Therapeutics to Announce First Quarter 2019 Financial Results

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody(TM) therapeutic...

CTMX : 11.26 (+3.02%)
Shares of CTMX Down 25.1% Since Downtrend Call on Shares

SmarTrend identified a Downtrend for Cytomx Therapeut (NASDAQ:CTMX) on February 27th, 2019 at $12.97. In approximately 2 months, Cytomx Therapeut has returned 25.11% as of today's recent price of $9.71....

CTMX : 11.26 (+3.02%)
Analysts Estimate CytomX Therapeutics (CTMX) to Report a Decline in Earnings: What to Look Out for

CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CTMX : 11.26 (+3.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade CTMX with:

Business Summary

CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered...

See More

Key Turning Points

2nd Resistance Point 11.47
1st Resistance Point 11.36
Last Price 11.26
1st Support Level 11.05
2nd Support Level 10.85

See More

52-Week High 27.20
Fibonacci 61.8% 20.22
Fibonacci 50% 18.07
Fibonacci 38.2% 15.92
Last Price 11.26
52-Week Low 8.94

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar